AEON Biopharma (formerly Alphaeon and Priveterra Acquisition) is a clinical-stage biopharmaceutical company developing a botulinum toxin complex for debilitating medical conditions, with an initial focus on neurology and gastroenterology. It offers ABP-450, a prabotulinumtoxinA injection that causes chemical denervation of the muscle resulting in a localized reduction of muscle activity.